Drug Profile

BCX 17725

Alternative Names: BCX-17725

Latest Information Update: 26 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

05 May 2025 The US FDA clears an IND application for a phase I trial in Netherton-Syndrome in USA
02 Oct 2024 Phase-I clinical trials in Netherton-Syndrome in Australia (SC) (NCT06539507)
23 Aug 2024 BioCryst Pharmaceuticals plans a first in human phase I/Ib trial for Netherton syndrome (In Volunteers) in Australia in September 2024 (NCT06539507)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com